Article Text

Journal club
Riociguat, a novel therapy for pulmonary hypertension?
  1. Sarah-Jane Bailey
  1. Correspondence to Dr Sarah-Jane Bailey, CT2, University Hospital Lewisham NHS Trust, Department of Respiratory Medicine, Lewisham High Street, London SE13 6LH, UK; sarah-jane.bailey{at}

Statistics from

This phase three, double-blind, randomised, placebo-controlled, multicentre study was carried out in 30 countries. It compared riociguat (maximum dose 2.5 mg three times a day) with placebo in the treatment of symptomatic pulmonary hypertension.

The primary end point was change in baseline walking distance over 6 min assessed after 12 weeks of treatment. Patients in the riociguat group improved by …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.